Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Immunoassay | 4 | 2021 | 4485 | 0.18 | Why? |
| Trypanosomiasis, African | 1 | 2017 | 31 | 0.17 | Why? |
| Dried Blood Spot Testing | 1 | 2021 | 383 | 0.17 | Why? |
| Genetic Testing | 1 | 2020 | 395 | 0.16 | Why? |
| England | 7 | 2021 | 5116 | 0.16 | Why? |
| Hemorrhagic Fever, Ebola | 2 | 2017 | 1475 | 0.15 | Why? |
| Antibodies, Viral | 11 | 2021 | 51949 | 0.14 | Why? |
| Melioidosis | 1 | 2015 | 50 | 0.14 | Why? |
| Anthrax | 1 | 2014 | 35 | 0.14 | Why? |
| Heroin | 1 | 2014 | 41 | 0.14 | Why? |
| Warfare | 1 | 2014 | 90 | 0.13 | Why? |
| Antibodies, Neutralizing | 4 | 2021 | 25288 | 0.13 | Why? |
| Ebolavirus | 1 | 2017 | 834 | 0.10 | Why? |
| DNA, Viral | 1 | 2020 | 2521 | 0.10 | Why? |
| Travel-Related Illness | 1 | 2017 | 1357 | 0.10 | Why? |
| Communicable Diseases, Imported | 1 | 2017 | 843 | 0.09 | Why? |
| Immunity, Cellular | 1 | 2021 | 3614 | 0.09 | Why? |
| Asymptomatic Infections | 3 | 2021 | 7218 | 0.08 | Why? |
| Blood Donors | 4 | 2021 | 2956 | 0.08 | Why? |
| Sierra Leone | 2 | 2017 | 267 | 0.08 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2021 | 4545 | 0.08 | Why? |
| Military Personnel | 1 | 2014 | 1097 | 0.07 | Why? |
| Inpatients | 1 | 2020 | 5161 | 0.07 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2021 | 5837 | 0.07 | Why? |
| Antigens, Viral | 1 | 2021 | 6298 | 0.06 | Why? |
| T-Lymphocytes | 1 | 2020 | 6670 | 0.06 | Why? |
| London | 2 | 2021 | 2166 | 0.06 | Why? |
| Immunization, Passive | 3 | 2021 | 10067 | 0.05 | Why? |
| Firefighters | 1 | 2020 | 93 | 0.05 | Why? |
| Mortality | 1 | 2017 | 7132 | 0.05 | Why? |
| Sensitivity and Specificity | 4 | 2021 | 22971 | 0.05 | Why? |
| United Kingdom | 4 | 2021 | 18046 | 0.05 | Why? |
| Communicable Diseases | 1 | 2014 | 2148 | 0.05 | Why? |
| Seroepidemiologic Studies | 3 | 2021 | 10017 | 0.05 | Why? |
| Interleukin-2 | 1 | 2021 | 443 | 0.05 | Why? |
| Health Personnel | 4 | 2021 | 29646 | 0.05 | Why? |
| History, 21st Century | 2 | 2017 | 1849 | 0.05 | Why? |
| Public Health | 3 | 2021 | 16359 | 0.05 | Why? |
| Police | 1 | 2020 | 243 | 0.04 | Why? |
| Antibody Formation | 2 | 2021 | 4038 | 0.04 | Why? |
| Secondary Care Centers | 1 | 2017 | 119 | 0.04 | Why? |
| Statistics, Nonparametric | 1 | 2020 | 1008 | 0.04 | Why? |
| Selection Bias | 1 | 2017 | 201 | 0.04 | Why? |
| Antibody Specificity | 1 | 2020 | 1328 | 0.04 | Why? |
| Humans | 21 | 2021 | 930598 | 0.04 | Why? |
| Bacillus anthracis | 1 | 2014 | 42 | 0.04 | Why? |
| Afghanistan | 1 | 2014 | 224 | 0.03 | Why? |
| Immunization Schedule | 1 | 2021 | 1305 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Soft Tissue Infections | 1 | 2014 | 116 | 0.03 | Why? |
| Limit of Detection | 1 | 2021 | 2698 | 0.03 | Why? |
| Early Diagnosis | 1 | 2021 | 2443 | 0.03 | Why? |
| Anti-Bacterial Agents | 1 | 2014 | 10083 | 0.03 | Why? |
| Case-Control Studies | 2 | 2021 | 17671 | 0.03 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.03 | Why? |
| Reagent Kits, Diagnostic | 1 | 2020 | 2149 | 0.03 | Why? |
| Nigeria | 1 | 2017 | 2292 | 0.02 | Why? |
| Phenotype | 1 | 2021 | 4037 | 0.02 | Why? |
| Self Report | 1 | 2021 | 3802 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Adult | 6 | 2021 | 244371 | 0.02 | Why? |
| Epidemiological Monitoring | 1 | 2021 | 3493 | 0.02 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.02 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.02 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.02 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.02 | Why? |
| Time Factors | 2 | 2021 | 31397 | 0.02 | Why? |
| RNA, Messenger | 1 | 2021 | 5131 | 0.02 | Why? |
| Middle Aged | 6 | 2021 | 270681 | 0.02 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.02 | Why? |
| Young Adult | 3 | 2021 | 93724 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 7868 | 0.02 | Why? |
| Male | 6 | 2021 | 367725 | 0.02 | Why? |
| Laboratories | 1 | 2017 | 2858 | 0.02 | Why? |
| Population Surveillance | 1 | 2021 | 4967 | 0.02 | Why? |
| Female | 6 | 2021 | 380317 | 0.02 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
| Cross-Sectional Studies | 2 | 2021 | 53120 | 0.02 | Why? |
| Symptom Assessment | 1 | 2017 | 4967 | 0.02 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.02 | Why? |
| Follow-Up Studies | 1 | 2021 | 17020 | 0.01 | Why? |
| Public Health Surveillance | 1 | 2014 | 3129 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2021 | 11041 | 0.01 | Why? |
| Zoonoses | 1 | 2014 | 3034 | 0.01 | Why? |
| Magnetic Resonance Imaging | 1 | 2017 | 6551 | 0.01 | Why? |
| Adolescent | 2 | 2021 | 86841 | 0.01 | Why? |
| Aged | 3 | 2021 | 215776 | 0.01 | Why? |
| Disease Outbreaks | 2 | 2017 | 27595 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
| Viral Load | 1 | 2017 | 15850 | 0.01 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.01 | Why? |
| Biomarkers | 1 | 2017 | 23361 | 0.01 | Why? |
| Risk Factors | 1 | 2021 | 71621 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2015 | 15421 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2014 | 43792 | 0.01 | Why? |
| Retrospective Studies | 1 | 2017 | 105322 | 0.00 | Why? |
| Animals | 1 | 2014 | 78931 | 0.00 | Why? |
Brooks's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(99)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(309)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_